Prohost Letter #379
Investors Concerns, Excitments and Expectations

It is understandable the fact that bullish and bearish analysts have opposite opinions (opposite wishes too) on biotech firms’ pipelines products and clinical trial results. They differ in assessing important news and in applying different criteria in their evaluation in order to establish proof of concept of their personal views. Articles are filling the media with contradicting interpretations of biotech firms’ clinical trial results and financial results, in addition to contradicting speculations about companies’ future sales revenues. As a consequence, analysts’ efforts to lure investors ended up creating overenthusiasm at . . .